Autolus Therapeutics plc (AUTL)

Market Cap	609.42M
Revenue (ttm)	10.09M
Net Income (ttm)	-270.23M
Shares Out	266.12M
EPS (ttm)	-1.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,149,404
Open	2.230
Previous Close	2.240
Day's Range	2.200 - 2.350
52-Week Range	2.200 - 7.450
Beta	2.00
Analysts	Strong Buy
Price Target	10.20 (+345.42%)
Earnings Date	Nov 12, 2024

About AUTL

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell ly...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 22, 2018
• Employees: 471
• Stock Exchange: NASDAQ
• Ticker Symbol: AUTL
• Website: https://www.autolus.com

Financial Performance

In 2023, Autolus Therapeutics's revenue was $1.70 million, a decrease of -73.30% compared to the previous year's $6.36 million. Losses were -$208.38 million, 40.0% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for AUTL stock is "Strong Buy." The 12-month stock price forecast is $10.2, which is an increase of 345.42% from the latest price.

Price Target

$10.2

(345.42% upside)

Analyst Consensus: Strong Buy